Welcome to our dedicated page for Avidity Biosciences SEC filings (Ticker: RNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avidity Biosciences, Inc. (Nasdaq: RNA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into how Avidity describes its Antibody Oligonucleotide Conjugates (AOCs™) platform, its late-stage neuromuscular programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), and its broader pipeline in precision cardiology and immunology.
Current reports on Form 8-K are especially important for tracking material events at Avidity. Recent 8-K filings have covered topics such as the definitive merger agreement with Novartis AG, the related Separation and Distribution Agreement for the spin-off or sale of early-stage precision cardiology programs into SpinCo, positive clinical data from the EXPLORE44® and EXPLORE44-OLE™ trials of delpacibart zotadirsen (del-zota) in DMD44, and regulatory milestones including Breakthrough Therapy designation and updated BLA submission timing for del-zota. Other 8-Ks detail public equity offerings, amendments to equity incentive plans, and executive compensation arrangements in connection with the proposed merger.
Investors and analysts can also use Avidity’s SEC filings to confirm listing information for its common stock (trading under the symbol RNA on The Nasdaq Global Market), review descriptions of SpinCo and the planned spin-off structure, and understand the conditions, termination provisions and timing expectations associated with the Novartis transaction. These filings often reference additional documents such as proxy statements, registration statements for SpinCo and financial reports that further explain Avidity’s operations, risk factors and capital structure.
On Stock Titan, Avidity’s filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as clinical program updates, collaboration milestones, merger terms and changes in executive compensation. Real-time updates from EDGAR, combined with structured access to Forms 8-K and other filings, make this page a practical starting point for reviewing Avidity’s regulatory history, including material events related to its AOC platform, neuromuscular pipeline and the proposed acquisition by Novartis.
Avidity Biosciences director and CEO Sarah Boyce exercised 50,000 vested stock options at an exercise price of $1.24 and concurrently sold 50,000 common shares on 09/05/2025. The sales produced a weighted-average sale price of $49.9487 per share, with sale prices in the range $49.76 to $50.12. After these transactions, Ms. Boyce directly beneficially owns 305,871 shares and holds derivative rights to 50,000 shares exercisable through 12/17/2029, for a total direct beneficial ownership reported as 1,022,015 derivative-linked shares and 355,871 pre-transaction common shares as shown on the Form 4. The option exercise and sales were executed under a Rule 10b5-1 trading plan adopted August 15, 2024.
Eric Mosbrooker, Chief Commercial Officer of Avidity Biosciences, Inc. (RNA), reported option exercise and concurrent sales executed on 09/03/2025 under a previously adopted Rule 10b5-1 trading plan. He exercised 6,563 stock options at an exercise price of $9.05 per share, resulting in ownership of 61,563 shares after the transaction. On the same date he sold 6,563 shares in multiple transactions at a weighted-average price of $47.0723 (prices ranged $46.13–$47.66). The reporting person adopted the 10b5-1 plan on September 11, 2024. Option vesting is monthly at 1/48th starting January 1, 2024, with full vesting on the fourth anniversary.
Avidity Biosciences (RNA) filed a Form 144 reporting a proposed sale of 50,000 common shares to be executed through Morgan Stanley Smith Barney on 09/05/2025, with an aggregate market value of $2,423,500 based on the filing. The shares were acquired on 09/05/2025 by exercise of stock options and paid in cash. The filer also reported prior 10b5-1 sales of 25,000 shares on 08/28/2025 generating gross proceeds of $1,234,700. The filing includes the required representation that the seller is not aware of undisclosed material adverse information and references reliance on Rule 10b5-1 trading instructions where applicable.
Form 144 filed for Avidity Biosciences (RNA) reports a proposed sale of common stock totaling 95,052 shares with an aggregate market value of $4,752,600, to be sold through UBS Financial Services on Nasdaq on 09/05/2025. The filing lists the issuer's total shares outstanding as 128,653,337, so the proposed sale represents a small fraction of the company’s outstanding stock.
The filer shows prior acquisitions including a stock option exercise on 09/05/2025 for 14,500 shares paid in cash and long-held shares acquired in 2018 and 2012 totaling 80,552 shares. The filing also discloses multiple related-party sales on 08/06/2025 totaling 97,054 shares with combined gross proceeds reported.
Avidity Biosciences (RNA) filing a Form 144 shows a proposed sale of 19,688 common shares with an aggregate market value of $929,864.24 to be executed on 09/03/2025 through Morgan Stanley Smith Barney on NASDAQ. The filing indicates these shares were acquired the same day by exercise of stock options and paid in cash. The notice also discloses prior Rule 10b5-1 sales by the same person on 08/06/2025 totaling 130,807 shares for $5,763,699.79. Several standard filer and issuer identification fields in the form are blank or not provided in the text.
Kathleen P. Gallagher, Chief Program Officer at Avidity Biosciences, Inc. (RNA), reported a sell-to-cover transaction tied to RSU vesting. On September 2, 2025 she sold 188 shares of Avidity common stock at $47.42 per share to satisfy tax withholding from RSUs that vested on August 30, 2025. The filing states the sale was executed under the issuer's sell-to-cover election and pursuant to an instruction letter intended to meet the affirmative defense conditions of Rule 10b5-1. After the transaction she beneficially owned 50,204 shares (direct).
Sarah Boyce, President and CEO and a director of Avidity Biosciences, Inc. (RNA), exercised options and sold shares on 08/28/2025 under a previously adopted Rule 10b5-1 trading plan. The reporting person exercised a stock option to acquire 25,000 shares at an exercise price of $1.24 and contemporaneously sold 25,000 shares at a weighted-average sales price of $49.388 per share (sales ranged $49.23–$49.52). The filings show direct beneficial ownership of common stock decreased from 330,871 shares before the sale to 305,871 shares after the sale. The option award exercised was fully vested and exercisable as of the transaction date, and Table II reports 25,000 underlying shares from the exercised option and a total of 1,072,015 derivative securities beneficially owned following the transaction as reported on the form. The trades were effected pursuant to a 10b5-1 plan adopted August 15, 2024.
Avidity Biosciences (RNA) filed a Form 144 reporting the proposed sale of 25,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $1,195,500. The filing shows the shares were acquired and paid for on 08/28/2025 via exercise of stock options from the issuer, and the filer reports no securities sold in the past three months. The notice includes the filer’s representation that they are not aware of undisclosed material adverse information and contains the standard signature and certification language.
Steven George, Chief Medical Officer of Avidity Biosciences (RNA), exercised stock options and sold shares under a preexisting Rule 10b5-1 plan. On 08/22/2025 he exercised options to acquire 2,208 shares at an exercise price of $10.16 per share and simultaneously sold 2,208 shares in multiple transactions at a weighted-average sale price of $46.4047 per share, with individual sale prices ranging from $44.64 to $47.03. After these transactions he beneficially owned 41,075 shares before the sale and 38,867 shares following the sale. The option exercised was granted 01/20/2024, vests monthly in equal installments of 2,208 shares and becomes fully vested on 01/20/2028. The reporting person adopted the 10b5-1 plan on 06/12/2024.
Avidity Biosciences insider activity: Teresa McCarthy, Chief Human Resources Officer, effected option exercise and share sales under a Rule 10b5-1 plan on 08/15/2025. She exercised a stock option with a $22.34 exercise price for 10,000 shares and immediately sold 10,000 common shares in multiple transactions at a weighted-average price of $46.5632, with trade prices ranging $45.36 to $47.50. After these transactions the reporting person beneficially owned 97,130 shares of common stock and held options covering 100,000 shares. The option shares were fully vested as of the exercise date.
FAQ
What is the current stock price of Avidity Biosciences (RNA)?
What is the market cap of Avidity Biosciences (RNA)?
